HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

57.250

+1.5002.69%

Volume:1.98M

Turnover:113.31M

Market Cap:11.39B

PE:-40.37

High:59.150

Open:57.050

Low:55.400

Close:55.750

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.67

T/O Rate:1.00%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.418

ROE:-51.55%

ROA:-12.87%

PB:10.44

PE(LYR):-40.37

PS:45.59

Loading ...

Overview Company News Filings

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Enters Phase Ⅱ Trial With First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

THOMSON REUTERS

LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Nanjing Leads Biolabs enrolls first patient in Phase II LBL-024 gastric cancer trial

Orient Securities Maintains "Buy" Rating on LEADS BIOLABS-B with HK$103.06 Target Price

Leads Biolabs advances Opamtistomig Phase II biliary tract cancer trial to expansion phase

Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug

LEADS BIOLABS-B Surges Over 4% as Phase II Study for Biliary Tract Cancer Advances

Leads Biolabs Announces Phase II Biliary Tract Cancer Trial of Bispecific Antibody LBL-024 Moves to Expansion Phase

Bulletin Express

LEADS BIOLABS-B (09887): Phase II Study of Vilisin™ for Biliary Tract Cancer Progresses to Expansion Phase

Nanjing Leads Biolabs’ LBL-024 Phase II biliary tract cancer trial enters expansion phase

Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation

Leads Biolabs Maintains Stable Share Base in March 2026; Confirms Public-Float Compliance

Bulletin Express

LEADS BIOLABS-B Surges Over 10% in Morning Session Following AACR Abstract Acceptance

LEADS BIOLABS-B to Feature Two Preclinical Research Summaries at 2026 AACR Annual Meeting

Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters

Leads Biolabs Announces Board Reshuffle: Dr. Ni to Resign, Dr. Wu Nominated as Non-Executive Director, Nomination Committee Re-aligned

Bulletin Express

LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan

Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/stock/09887/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":57.25,"timestamp":1789978116009,"preClose":55.75,"halted":0,"volume":1976500,"delay":0,"changeRate":0.026905829596412557,"floatShares":198000000,"shares":199000000,"eps":-1.4179493194210175,"marketStatus":"Closed","change":1.5,"latestTime":"09-21 16:08:36","open":57.05,"high":59.15,"low":55.4,"amount":113306417,"amplitude":0.067265,"askPrice":57.25,"askSize":200,"bidPrice":57.15,"bidSize":2900,"shortable":3,"etf":0,"ttmEps":-1.6137106993449182,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":55.75,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":0.668432,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.417967,"volumeRatio":0.668432,"shares":199000000,"dividePrice":0,"high":59.15,"amplitude":0.067265,"preClose":55.75,"low":55.4,"week52Low":44.72,"pbRate":"10.44","psRate":"45.59","week52High":97.5,"institutionHeld":0,"latestPrice":57.25,"committee":0.870968,"eps":-1.4179666734658656,"divideRate":0,"volume":1976500,"delay":0,"ttmEps":-1.6137304492805926,"open":57.05,"prevYearClose":51,"prevWeekClose":55.75,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":61.5,"twentyDayClose":69.05,"sixtyDayClose":49.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1789574400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-18","current":-35.011688,"percent":0.795053,"low":-76.458084,"twenty":-45.532372,"median":-39.845109,"eighty":-34.761336,"high":-30.202688,"avg":-41.959033,"sd":9.633296,"marketCap":10878029200},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-11","current":-37.6607,"twenty":-45.564242,"median":-39.940552,"eighty":-34.761336,"marketCap":11746320320},{"date":"2026-09-18","current":-34.8313,"twenty":-45.532372,"median":-39.845109,"eighty":-34.761336,"marketCap":10878029200}],"updateTime":1789961379773},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629037319","title":"Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Enters Phase Ⅱ Trial With First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629037319?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:47","pubTimestamp":1776779229,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA3MNBBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172645376","title":"LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1172645376","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172645376?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:50","pubTimestamp":1776761442,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating LBL-024, a PD-L1/4-1BB bispecific antibody, for the treatment of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4585","PD","BK1161","BK4555","09887","BK4604","LU1169589451.USD","HK0000500386.USD","BK4588","TM","BK4099","LU1169590202.USD","HK0000252152.HKD","HK0000252160.HKD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629978089","title":"Nanjing Leads Biolabs enrolls first patient in Phase II LBL-024 gastric cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629978089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629978089?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:46","pubTimestamp":1776761186,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs enrolled first patient in an open-label, multi-center Phase II study of Opamtistomig  for first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.Trial will assess efficacy and safety, with no results presented yet.Program extends clinical development of LBL-024 beyond its registrational-stage work in extrapulmonary neuroendocrine carcinoma, where earlier China studies showed encouraging activity with a favorable safety profile.Company positioned LBL-024 as a differentiated PD-L1/4-1BB bispecific designed to combine checkpoint blockade with T-cell activation, supporting a broader solid-tumor strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7wmXld:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114070277","title":"Orient Securities Maintains \"Buy\" Rating on LEADS BIOLABS-B with HK$103.06 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1114070277","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114070277?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:30","pubTimestamp":1776760245,"startTime":"0","endTime":"0","summary":"Orient Securities has released a research report adjusting the earnings per share forecasts for LEADS BIOLABS-B (09887) for 2026-2028 to -1.41, -0.44, and 0.04 yuan respectively, based on the 2025...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","HK0000500386.USD","BK0012","BK1147","BK0028","BK0183","BK0276","BK1564","BK0188","HK0000252160.HKD","HK0000252152.HKD","03958","600958","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902219","title":"Leads Biolabs advances Opamtistomig Phase II biliary tract cancer trial to expansion phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902219","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902219?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:35","pubTimestamp":1775723712,"startTime":"0","endTime":"0","summary":"Leads Biolabs moved Opamtistomig  into expansion phase of a Phase II study in first-line advanced biliary tract cancer following positive safety run-in results.Results have already been presented internally as preliminary safety and early efficacy readouts from 20 patients, supporting accelerated enrollment with first patient now enrolled in expansion.Combination with chemotherapy was generally well tolerated, with no new safety signals observed.Early efficacy assessment showed encouraging tumor reduction trends, positioning program for a planned confirmatory study as more data mature.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLRPBb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","BK4112","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2095319765.USD","HK0000500386.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","HK0000252152.HKD","SG9999014013.SGD","IE00BGHQF748.EUR","09887","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","HK0000252160.HKD","NDAQ","BK4588","IE00BN0W2W23.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152091097","title":"Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1152091097","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152091097?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:46","pubTimestamp":1775699209,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.The company announced that the preliminary safety evaluation for the Phase II...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151050698","title":"LEADS BIOLABS-B Surges Over 4% as Phase II Study for Biliary Tract Cancer Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=1151050698","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151050698?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:44","pubTimestamp":1775699059,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4%, with the stock up 4.39% to HK$93.9 at the time of writing. The trading volume was HK$13.3778 million. On April 8, LEADS BIOLABS announced that the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","VXUS","HK0000252160.HKD","BK1161","09887","BK4588","HK0000252152.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191731000","title":"Leads Biolabs Announces Phase II Biliary Tract Cancer Trial of Bispecific Antibody LBL-024 Moves to Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1191731000","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191731000?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:41","pubTimestamp":1775637669,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for first-line treatment of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147799498","title":"LEADS BIOLABS-B (09887): Phase II Study of Vilisin™ for Biliary Tract Cancer Progresses to Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1147799498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147799498?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:38","pubTimestamp":1775637503,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the Phase II clinical study evaluating Vilisin™ (PD-L1/4-1BB bispecific antibody Opatisumimab, LBL-024) as a first-line treatment for advanced biliary tract...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","03160","BK4099","BK4555","BK4588","BK4604","HK0000252152.HKD","HK0000500386.USD","TM","BK4585","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619919","title":"Nanjing Leads Biolabs’ LBL-024 Phase II biliary tract cancer trial enters expansion phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625619919?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:33","pubTimestamp":1775637235,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs reported Phase II study of Opamtistomig , its PD-L1/4-1BB bispecific antibody, for first-line advanced biliary tract cancer has moved into expansion phase.Safety run-in phase completed preliminary assessment in 20 patients, supporting continuation on tolerability.Early efficacy readout showed an encouraging trend in tumor shrinkage, without disclosing detailed response figures.First patient has been enrolled in expansion phase as trial accelerates across multiple hospitals in China.Results have been presented as preliminary findings from safety run-in phase, with expansion-phase data expected in future updates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9tz0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09887","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192002926","title":"Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=1192002926","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192002926?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:34","pubTimestamp":1775018058,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164371785","title":"Leads Biolabs Maintains Stable Share Base in March 2026; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164371785","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164371785?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:06","pubTimestamp":1775012798,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital for the month ended 31 March 2026, according to its latest monthly return filed with Hong Kong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106696968","title":"LEADS BIOLABS-B Surges Over 10% in Morning Session Following AACR Abstract Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1106696968","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106696968?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:18","pubTimestamp":1775009902,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its shares rise more than 10% during the morning trading session. At the time of writing, the stock was up 8.99%, trading at HKD 80.65, with a turnover of HKD 32.19...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","HK0000500386.USD","BK1161","BK4585","HK0000252152.HKD","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178094448","title":"LEADS BIOLABS-B to Feature Two Preclinical Research Summaries at 2026 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1178094448","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178094448?lang=en_us&edition=fundamental","pubTime":"2026-03-31 17:00","pubTimestamp":1774947626,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that two preclinical pipeline research summaries will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The meeting is...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623304255","title":"Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters","url":"https://stock-news.laohu8.com/highlight/detail?id=2623304255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623304255?lang=en_us&edition=fundamental","pubTime":"2026-03-31 16:55","pubTimestamp":1774947327,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4zJN1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09887","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102586833","title":"Leads Biolabs Announces Board Reshuffle: Dr. Ni to Resign, Dr. Wu Nominated as Non-Executive Director, Nomination Committee Re-aligned","url":"https://stock-news.laohu8.com/highlight/detail?id=1102586833","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102586833?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:04","pubTimestamp":1774609494,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) reported three board-level changes that will take effect or be confirmed on 27 March 2026. Resignation of Non-Executive Director   • Dr. Ni Jia will...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116228132","title":"LEADS BIOLABS-B Nominates Wu Fenglan for Non-Executive Director Role","url":"https://stock-news.laohu8.com/highlight/detail?id=1116228132","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116228132?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609235,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Dr. Ni Jia has tendered her resignation as a non-executive director of the company, effective March 27, 2026. Following the recommendation of the board's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622284948","title":"Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2622284948","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622284948?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:54","pubTimestamp":1774608885,"startTime":"0","endTime":"0","summary":"Non-executive director Ni Jia resigned, effective March 27, 2026.The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2Y01zT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109981661.USD","SGXZ57979304.SGD","LU0225771236.USD","BK1588","LU0306807586.USD","LU0545562505.USD","LU1202635105.USD","LU0971552673.USD","LU1035777561.USD","HK0000252160.HKD","LU1481599808.USD","LU0971552830.HKD","LU1015430645.USD","LU1228905540.USD","IE00BWDBJ516.SGD","LU0321505439.SGD","LU0289739699.SGD","IE0034235071.USD","LU1400636491.USD","LU1983299246.USD","SG9999001176.SGD","LU0203345920.USD","LU0211331839.USD","IE00B3T34201.USD","LU1309081286.SGD","BK1161","LU0575583348.USD","LU2488822045.USD","SG9999001176.USD","HK0000500386.USD","LU0058720904.USD","09688","LU1064927863.SGD","LU0306806265.USD","LU1228905037.USD","LU1670756490.USD","LU1645745479.HKD","09887","BK1574","LU1400636657.SGD","SG9999013999.USD","IE00BQJZX424.USD","LU1481600234.SGD","LU1046248800.SGD","LU0225284248.USD","LU1302929846.USD","GSK.UK","LU0985481810.HKD","LU0321505868.SGD","LU0161305163.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124822191","title":"LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124822191","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124822191?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:11","pubTimestamp":1774602704,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181768552","title":"Leads Biolabs 2025 Results: Revenue Reaches RMB177.26 Million on Up-Front Licensing; Net Loss Narrows 29.8% to RMB211.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1181768552","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181768552?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:04","pubTimestamp":1774602242,"startTime":"0","endTime":"0","summary":"Leads Biolabs (Nanjing Leads Biolabs Co., Ltd.) released its audited 2025 annual results. Financial Highlights   • Revenue: RMB177.26 million, versus zero in 2024, driven entirely by upfront and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":142,"code":"91000000","status":"200"}]}}